How does tesofensine compare to GLP-1 drugs like semaglutide?

Different mechanisms entirely. GLP-1s mimic a gut hormone that signals fullness and slows gastric emptying. Tesofensine increases serotonin, noradrenaline, and dopamine levels in the brain, directly reducing appetite and increasing satiety centrally. GLP-1s produce more weight loss (13-15% vs 9-10%) but tesofensine works through the reward pathway, which may be particularly effective for compulsive or emotional eating. They could potentially be combined for additive effects.

Is tesofensine safe? What about the heart rate increase?

The main concern is a dose-dependent heart rate increase — about 7.4 bpm at 0.5 mg. This is why the combination product Tesomet pairs tesofensine with metoprolol (a beta-blocker) to offset cardiovascular effects. At the 0.5 mg dose, blood pressure was not significantly elevated vs placebo. The 1.0 mg dose showed stronger weight loss (10.6%) but more side effects, which is why 0.5 mg is considered the therapeutic dose.

Where is tesofensine available?

Tesofensine received a favorable regulatory opinion in Mexico in 2023 for obesity treatment. It is not FDA-approved in the US. Some US compounding pharmacies offer tesofensine, though the regulatory basis for compounding an unapproved drug substance is more complex than for compounds that are components of approved products. Tesomet (tesofensine + metoprolol) has FDA orphan drug designation for hypothalamic obesity and Prader-Willi syndrome.

Tesofensine

A triple monoamine reuptake inhibitor (serotonin, noradrenaline, dopamine) that produced up to 10.6% weight loss in Phase 2 trials — roughly double the efficacy of older appetite suppressants. Approved in Mexico; not yet FDA-approved.

ModerateLimited Data

What is Tesofensine?

Tesofensine is an oral small-molecule triple monoamine reuptake inhibitor that blocks the reuptake of serotonin, noradrenaline, and dopamine — the three neurotransmitters most involved in appetite, satiety, and reward. Originally developed by NeuroSearch for Alzheimer's and Parkinson's disease, weight loss was observed as a "side effect" in those trials, redirecting development toward obesity. In a Phase 2 trial published in The Lancet (203 patients, 24 weeks), tesofensine 0.5 mg produced 9.2% body weight loss — roughly double what sibutramine or rimonabant achieved. It is not a peptide, but is widely discussed alongside peptides in the weight loss and compounding pharmacy space. Tesofensine received regulatory approval in Mexico in 2023 and has FDA orphan drug designation for hypothalamic obesity and Prader-Willi syndrome (as Tesomet, combined with metoprolol).

Why People Talk About It

Weight loss via appetite suppression (up to 10.6% in trials)

Moderate

Dopaminergic appetite control (different pathway from GLP-1s)

Moderate

Hypothalamic obesity (FDA orphan drug designation)

Emerging

Prader-Willi syndrome hyperphagia (FDA orphan drug designation)

Preliminary

Potential combination with GLP-1 agonists for additive weight loss

Limited

How It Works

Tesofensine blocks the recycling of three brain chemicals — serotonin, noradrenaline, and dopamine — that control appetite, mood, and reward. By keeping more of these neurotransmitters active in the brain, it reduces hunger, increases the feeling of fullness, and decreases the reward drive to eat. It also slightly increases energy expenditure. Recent research shows it specifically silences hunger-promoting neurons in the hypothalamus.

Common Questions

Safety Information

Important Safety Notes

Common Side Effects

Dry mouthNauseaConstipation or diarrheaInsomniaHeadacheHeart rate increase (~7.4 bpm at 0.5 mg dose)

Cautions

• Not FDA-approved in the US
• Heart rate increase is dose-dependent — cardiovascular monitoring recommended
• Monoamine reuptake inhibition carries psychiatric risk (anxiety, mood changes) in susceptible individuals
• Tesomet combination (with metoprolol) has better cardiovascular safety profile than tesofensine alone
• May interact with SSRIs, SNRIs, MAOIs, and other serotonergic drugs — serotonin syndrome risk

What We Don't Know

Long-term cardiovascular safety beyond 24 weeks is not established in the published Phase 2 data. Psychiatric adverse event rates in larger populations are unclear — Phase 3 data from the Mexico program has not been fully published. Whether combining tesofensine with GLP-1 agonists is safe and effective is untested.

Published Research

6 studies

Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons.

PreclinicalPMID: 38656972

Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.

Randomized Controlled TrialPMID: 35294397

Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects.

ReviewPMID: 24239329

Tesofensine induces appetite suppression and weight loss.

PreclinicalPMID: 23932919

Tesofensine--a novel potent weight loss medicine.

ReviewPMID: 19548858

Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.

203 patients, 24 weeks, up to 10.6% weight loss

Randomized Controlled TrialPMID: 18950853

Mechanism of Action

Tesofensine is a triple monoamine reuptake inhibitor that blocks the presynaptic transporters for serotonin (SERT), noradrenaline (NET), and dopamine (DAT), increasing synaptic concentrations of all three neurotransmitters. The primary weight loss mechanism is appetite suppression (reduced food intake), with a minor contribution from increased energy expenditure. A 2024 study revealed that tesofensine silences GABAergic neurons in the lateral hypothalamus — a brain region directly involved in feeding behavior — providing a specific neuroanatomical target for its anorectic effects. The triple reuptake profile distinguishes it from SSRIs/SNRIs (which affect only 1-2 monoamines) and from GLP-1 agonists (which work through peripheral gut hormone signaling). In Phase 2 (203 patients, 24 weeks, Lancet), dose-dependent weight loss was observed: 4.5% (0.25 mg), 9.2% (0.5 mg), and 10.6% (1.0 mg) vs 2.0% placebo, with 0.5 mg considered the optimal therapeutic dose balancing efficacy and cardiovascular safety.

Evidence Snapshot

Overall Confidence55%

Human Clinical Evidence

Moderate. Phase 2 RCT published in The Lancet (203 patients, 24 weeks, 5 Danish centers): dose-dependent weight loss up to 10.6%, with 0.5 mg producing 9.2% loss (double sibutramine). Phase 3 completed in Mexico by Saniona's partner Medix, leading to regulatory approval. Tesomet (tesofensine + metoprolol) tested in hypothalamic obesity RCT showing significant weight loss with improved cardiovascular safety profile. FDA orphan drug designation for hypothalamic obesity and Prader-Willi syndrome.

Animal / Preclinical

Strong. Diet-induced obese rat models showed sustained weight loss superior to sibutramine and rimonabant. A 2024 study identified the specific neuronal mechanism: silencing of GABAergic lateral hypothalamic neurons (PMID: 38656972). Preclinical work supports both appetite suppression and modest energy expenditure increase.

Mechanistic Rationale

Strong. Triple monoamine reuptake inhibition for appetite control is pharmacologically well-established. The lateral hypothalamic GABAergic neuron silencing provides a specific mechanistic basis. The dopaminergic component distinguishes tesofensine from earlier serotonin-only approaches and may address reward-driven eating.

Forms & Administration

Tesofensine is taken as a once-daily oral tablet, typically 0.5 mg. The 0.25 mg dose is effective but less potent; the 1.0 mg dose produces more weight loss but more side effects. Tesomet combines tesofensine with metoprolol to manage heart rate effects. Available through some US compounding pharmacies with a prescription, and approved in Mexico for obesity.

Use Cases & Evidence Levels

Weight loss via appetite suppression (up to 10.6% in trials)

Moderate70%

Dopaminergic appetite control (different pathway from GLP-1s)

Moderate70%

Hypothalamic obesity (FDA orphan drug designation)

Emerging50%

Prader-Willi syndrome hyperphagia (FDA orphan drug designation)

Preliminary30%

Potential combination with GLP-1 agonists for additive weight loss

Limited15%

Safety Profile

Safety Information

Common Side Effects

Dry mouthNauseaConstipation or diarrheaInsomniaHeadacheHeart rate increase (~7.4 bpm at 0.5 mg dose)

Cautions

• Not FDA-approved in the US
• Heart rate increase is dose-dependent — cardiovascular monitoring recommended
• Monoamine reuptake inhibition carries psychiatric risk (anxiety, mood changes) in susceptible individuals
• Tesomet combination (with metoprolol) has better cardiovascular safety profile than tesofensine alone
• May interact with SSRIs, SNRIs, MAOIs, and other serotonergic drugs — serotonin syndrome risk

What We Don't Know

Published Research

6 studies

Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons.

PreclinicalPMID: 38656972

Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.

Randomized Controlled TrialPMID: 35294397

Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects.

ReviewPMID: 24239329

Tesofensine induces appetite suppression and weight loss.

PreclinicalPMID: 23932919

Tesofensine--a novel potent weight loss medicine.

ReviewPMID: 19548858

Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.

203 patients, 24 weeks, up to 10.6% weight loss

Randomized Controlled TrialPMID: 18950853

Related Peptides

Semaglutide

StrongBeginner

A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, one of the most widely prescribed peptide drugs.

Tirzepatide

StrongBeginner

A dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.

Liraglutide

StrongBeginner

A GLP-1 receptor agonist FDA-approved for diabetes (Victoza) and weight management (Saxenda), the predecessor to semaglutide.

Orforglipron

Moderate

Foundayo (orforglipron) is Eli Lilly's oral small-molecule GLP-1 receptor agonist. Phase 3 trials show up to 11.2% weight loss via daily pill — no injections required. Regulatory submissions expected 2026.

AOD-9604

EmergingBeginner

A modified fragment of human growth hormone studied specifically for fat metabolism without the growth-promoting effects of full GH.

Quick Facts

Class: Monoamine Reuptake Inhibitor
Evidence: Moderate
Safety: Limited Data
Updated: Apr 2026
Citations: 6PubMed

Also known as

NS2330TE

Evidence Score

Overall Confidence55%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.